PCPaola Carioni

Paola Carioni

*This is an algorithmically generated author record based on publicly available information.

Paola Carioni has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hemodiafiltration versus High-Flux Hemodialysis and Risk of Mortality

    by Giovanni F.M. Strippoli, Giovanni Tripepi, Bernard Canaud, Stefano Stuard, Franklin W. Maddux, Len A. Usvyat, Paola Carioni, Matteo Savoia, Germaine Wong, Carmine Zoccali

    Key Points: Randomized trials suggested that hemodiafiltration improved survival over high-flux hemodialysis, but real-world evidence is limited. Target trial emulation showed that hemodiafiltration was associated with lower mortality than high-flux hemodialysis. The findings supported broader use of hemodiafiltration when technically feasible and clinically appropriate. Background: Randomized trials suggest that high-volume postdilution hemodiafiltration (HDF) may improve survival compared with high-flux hemodialysis, but evidence from routine clinical practice and from regions underrepresented in trials remains limited. Methods: We emulated a target trial comparing HDF with high-flux hemodialysis using data from European Clinical Database, a multinational registry of dialysis patients treated in 8 European countries. Adults receiving thrice-weekly in-center dialysis between 2014 and 2019 were eligible. Follow-up began 91 days after dialysis initiation. Sustained treatment strategies were defined as receipt of the assigned modality for at least 90% of sessions. Inverse probability weighting was used to emulate randomized treatment assignment. The primary outcome was all-cause mortality, with kidney transplantation treated as a competing event. Results: Among 19,539 eligible patients at day 91, inverse probability weighting created a weighted pseudopopulation of 19,758 patients (8641 HDF; 11,117 hemodialysis). During a median follow-up of 16 months (interquartile range, 6–32), 4282 deaths occurred. HDF was associated with a lower risk of all-cause mortality compared with high-flux hemodialysis (hazard ratio, 0.72; 95% confidence interval, 0.67 to 0.77). At 2 years, the weighted cumulative incidence of death was 20.6% in the HDF group and 22.3% in the hemodialysis group, corresponding to an absolute risk reduction of 1.7% points. The results were consistent across sensitivity analyses, including analyses accounting for country, competing risks, informative censoring, protocol adherence, and an intention-to-treat–like exposure definition. The association was broadly similar across prespecified subgroups, with only a stronger relative benefit observed among patients with preexisting cardiovascular disease (interaction P < 0.001). Higher delivered convective volumes were associated with better survival; however, these findings should be interpreted cautiously because higher convective volumes may reflect patient stability and center expertise rather than a causal dose–response relationship. Conclusions: In this large multinational target trial emulation, sustained high-volume postdilution HDF was associated with lower mortality than high-flux hemodialysis.


  • Open Access

    Real-World Hospitalization Outcomes with On-Line Hemodiafiltration Versus High-Flux Hemodialysis

    by Yan Zhang, Anke Winter, Linda H. Ficociello, Belén Alejos Ferrera, Paola Carioni, Christian Apel, Otto Arkossy, Michael Anger, Robert Kossmann, Len A. Usvyat, et al.

    Key Points: Compared with high-flux hemodialysis, postdilution high volume hemodiafiltration was associated with a lower number of hospital admissions. Compared with high-flux hemodialysis, postdilution high volume hemodiafiltration was associated with reduced days spent in the hospital. Background: Patients with ESKD undergoing hemodialysis experience high rates of hospitalizations and mortality, partly due to the incomplete removal of some toxic uremic molecules. To improve outcomes, multiple modalities of kidney replacement therapy have been developed, including high-flux hemodialysis and on-line hemodiafiltration (HDF). Notably, on-line high-volume HDF (HV-HDF) has demonstrated mortality benefits over high-flux hemodialysis in some randomized trials. Methods: This retrospective cohort study evaluated hospitalization outcomes among in-center dialysis patients treated with HV-HDF and high-flux hemodialysis at Fresenius Medical Care NephroCare centers across Europe, the Middle East, and Africa between January 2019 and December 2022. Data were extracted from the European Clinical Database. The primary outcome was all-cause hospitalization; secondary outcomes included cause-specific hospitalizations. Negative binomial regression was used to estimate incidence rate ratios (IRRs) for hospital outcomes, incorporating inverse probability of treatment weighting to adjust for baseline differences between treatment groups. Results: A total of 71,669 patients were included, with 45% receiving hemodialysis and 55% receiving HDF. During the follow-up period, patients in the HDF group underwent a total of 12,741,453 HDF treatments, with a mean convection volume of 25.8 L (84% with CV≥23L). Compared with hemodialysis, treatment with HDF was associated with a lower incidence of both hospital admissions (adjusted IRR, 0.80; 95% confidence interval, 0.79 to 0.82) and days spent in the hospital (adjusted IRR, 0.80; 95% confidence interval, 0.78 to 0.82). These reductions were consistent across subgroups analyzed and across most major causes of hospitalization, including cardiovascular disease, infections, and fluid-related complications. Conclusions: In this large, real-world cohort spanning multiple regions and dialysis centers, HV-HDF was associated with significantly lower rates of both hospital admissions and days spent in the hospital compared with treatment with high-flux hemodialysis. These findings suggest that HV-HDF may have the potential to reduce morbidity in patients with ESKD.


  • Long term fluid volume fluctuations and mortality in kidney failure patients on long term hemodialysis treatment

    by Carmine Zoccali, Giovanni Tripepi, Paola Carioni, Francesca Mallamaci, Matteo Savoia, Len A. Usvyat, Franklin W. Maddux, Stefano Stuard


  • Antihypertensive Drug Treatment and the Risk for Intrahemodialysis Hypotension

    by Carmine Zoccali, Giovanni Tripepi, Paola Carioni, Edouard L. Fu, Friedo Dekker, Vianda Stel, Kitty J. Jager, Francesca Mallamaci, Jeffrey L. Hymes, Franklin W. Maddux, et al.

    Key Points: Antihypertensive medications are often used by hemodialysis patients, and intradialytic hypotension is a common complication in these patients. The study emulates a randomized clinical trial comparing antihypertensive drug treatment for the risk of hemodialysis hypotension in 4072 incident patients. Compared with calcium antagonists, β and α–β blockers, angiotensin converting enzyme inhibitors or angiotensin II antagonists, and diuretics may increase the risk of hemodialysis hypotension. Background: Antihypertensive medications are often prescribed to manage hypertension in hemodialysis patients, and intradialytic hypotension (IDH) is a common complication in these patients. We investigated the risk of IDH in incident hemodialysis patients who initiated treatment with antihypertensive drugs in monotherapy. Methods: The study was conducted as an emulation of a randomized clinical trial in 4072 incident hemodialysis patients who started antihypertensive drug treatment between January 2016 and December 2019. The primary outcome was the occurrence of IDH during hemodialysis sessions. The generalized estimating equation analysis was adjusted by inverse probability treatment weighting. Results: Calcium channel blocker (CCB) use was associated with an IDH incidence rate of 7.4 events per person-year (95% confidence interval [CI], 6.2 to 8.6). Compared with CCB use, use of β and α–β blockers was strongly associated with a higher likelihood of IDH (odds ratio [OR] [95% CI, 2.27; 1.50 to 3.43]). The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (OR [95% CI, 1.71; 1.14 to 2.57]) and diuretics (OR [95% CI, 1.52; 1.07 to 2.16]) were also associated with a higher likelihood of IDH compared with CCB use. Conclusions: The study suggests that using β and α–β blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and diuretics may increase the risk of IDH in hemodialysis patients compared with CCB use.


  • Open Access

    Enhanced Sentinel Surveillance System for COVID-19 Outbreak Prediction in a Large European Dialysis Clinics Network

    by Francesco Bellocchio, Paola Carioni, Caterina Lonati, Mario Garbelli, Francisco Martínez-Martínez, Stefano Stuard, Luca Neri

    Accurate predictions of COVID-19 epidemic dynamics may enable timely organizational interventions in high-risk regions. We exploited the interconnection of the Fresenius Medical Care (FMC) European dialysis clinic network to develop a sentinel surveillance system for outbreak prediction. We developed an artificial intelligence-based model considering the information related to all clinics belonging to the European Nephrocare Network. The prediction tool provides risk scores of the occurrence of a COVID-19 outbreak in each dialysis center within a 2-week forecasting horizon. The model input variables include information related to the epidemic status and trends in clinical practice patterns of the target clinic, regional epidemic metrics, and the distance-weighted risk estimates of adjacent dialysis units. On the validation dates, there were 30 (5.09%), 39 (6.52%), and 218 (36.03%) clinics with two or more patients with COVID-19 infection during the 2-week prediction window. The performance of the model was suitable in all testing windows: AUC = 0.77, 0.80, and 0.81, respectively. The occurrence of new cases in a clinic propagates distance-weighted risk estimates to proximal dialysis units. Our machine learning sentinel surveillance system may allow for a prompt risk assessment and timely response to COVID-19 surges throughout networked European clinics.


  • Open Access

    SO063PRE-DIALYSIS FLUID STATUS MODIFIES THE RELATION BETWEEN PRE-DIALYSIS SYSTOLIC BLOOD PRESSURE AND OUTCOME IN PREVALENT HEMODIALYSIS PATIENTS

    by Marijke Dekker, Constantijn Konings, Bernard Canaud, Paola Carioni, Adrian Guinsburg, Magdalena Madero, Jeroen Van Der Net, Jochen Raimann, Frank Van Der Sande, Len Usvyat, et al.

    INTRODUCTION AND AIMS: Pre-dialysis fluid overload (FO) is a risk factor for mortality and the most frequent cause of elevated pre-dialysis systolic blood pressure (SBP). However, especially low pre-dialysis SBP is associated with increased mortality in hemodialysis (HD) patients. Whether the combination of pre-dialysis SBP and fluid status (FS) modifies the association with mortality has not yet been investigated. The objective of this study was to investigate the interaction between pre-dialysis FS and pre-dialysis SBP in the association with mortality.

  • Open Access

    SP633RED BLOOD CELL DISTRIBUTION WIDTH ASSOCIATES WITH ALL-CAUSE MORTALITY

    by Xiaoling Ye, Bernard Canaud, Paola Carioni, Jeroen Kooman, Frank Sande, Albert Power, Len Usvyat, Peter Kotanko, Jochen Raimann

    INTRODUCTION AND AIMS: Red cell distribution width (RDW) is a marker used for the differentiation of anemias and it is known to be elevated in most cases of iron, vitamin B12 and folate deficiencies. A growing body of evidence suggests an association of RDW with outcomes such as hospitalizations and mortality in the general population, chronic diseases such as heart failure, and more recently also chronic kidney disease. We aimed to analyze the relationship of RDW to all-cause mortality in a large European cohort of hemodialysis patients of the international MOnitoring Dialysis Outcomes (MONDO) initiative.

  • A comparative study of the risk profile of hemodialysis patients in a for profit network and in two regional registries of the Italian Society of Nephrology

    by Maurizio Postorino, Claudia Amato, Elena Mancini, Paola Carioni, Graziella D’arrigo, Attilio Di Benedetto, Fabrizio Cerino, Carmela Marino, Antonio Vilasi, Giovanni Tripepi, et al.

    In 2013, the Italian Society of Nephrology joined forces with Nephrocare-Italy to create a clinical research cohort of patients on file in the data-rich clinical management system (EUCLID) of this organization for the performance of observational studies in the hemodialysis (HD) population. To see whether patients in EUCLID are representative of the HD population in Italy, we set out to compare the whole EUCLID population with patients included in the regional HD registries in Emilia-Romagna (Northern Italy) and in Calabria (Southern Italy), the sole regions in Italy which have systematically collected an enlarged clinical data set allowing comparison with the data-rich EUCLID system. An analysis of prevalent and incident patients in 2010 and 2011 showed that EUCLID patients had a lower prevalence of coronary heart disease, peripheral vascular disease, heart failure, valvular heart disease, liver disease, peptic ulcer and other comorbidities and risk factors and a higher fractional urea clearance (Kt/V) than those in the Emilia Romagna and Calabria registries. Accordingly, survival analysis showed a lower mortality risk in the EUCLID 2010 and 2011 cohorts than in the combined two regional registries in the corresponding years: for 2010, hazard ratio (HR) EUCLID vs. Regional registries: 0.80 [95% confidence interval: 0.71–0.90]; for 2011, HR: 0.76 [0.65–0.90]. However, this difference was nullified by statistical adjustment for the difference in comorbidities and risk factors, indicating that the longer survival in the EUCLID database was attributable to the lower risk profile of patients included in that database. This preliminary analysis sets the stage for future observational studies and indicates that appropriate adjustment for difference in comorbidities and risk factors is needed to generalize to the Italian HD population analyses based on the data-rich EUCLID database.


  • Open Access

    Seasonal variations in mortality and clinical indicators in international hemodialysis populations from the MONDO registry

    by the Monitoring Dialysis Outcomes (MONDO) consortium, Adrian M. Guinsburg, Len A. Usvyat, Michael Etter, Xiaoqi Xu, Stephan Thijssen, Daniele Marcelli, Bernard Canaud, Cristina Marelli, Claudia Barth, et al.

    Seasonal mortality differences have been reported in US hemodialysis (HD) patients. Here we examine the effect of seasons on mortality, clinical and laboratory parameters on a global scale. Databases from the international Monitoring Dialysis Outcomes (MONDO) consortium were queried to identify patients who received in-center HD for at least 1 year. Clinics were stratified by hemisphere and climate zone (tropical or temperate). We recorded mortality and computed averages of pre-dialysis systolic blood pressure (pre-SBP), interdialytic weight gain (IDWG), serum albumin, and log C-reactive protein (CRP). We explored seasonal effects using cosinor analysis and adjusted linear mixed models globally, and after stratification. Data from 87,399 patients were included (northern temperate: 63,671; northern tropical: 7,159; southern temperate: 13,917; southern tropical: 2,652 patients). Globally, mortality was highest in winter. Following stratification, mortality was significantly lower in spring and summer compared to winter in temperate, but not in tropical zones. Globally, pre-SBP and IDWG were lower in summer and spring as compared to winter, although less pronounced in tropical zones. Except for southern temperate zone, serum albumin levels were higher in winter. CRP levels were highest in winter. Significant global seasonal variations in mortality, pre-SBP, IDWG, albumin and CRP were observed. Seasonal variations in mortality were most pronounced in temperate climate zones.